The database will be most useful for patients if it enables comparisons to be made between different medicinal products. As a first step, therefore, the aim should be to facilitate a comparison of efficacy, reactions and contraindications on the basis of the information already authorised for the package leaflet. This is both technically and legally simple as the information is already authorised for publication and firms cannot therefore characterise it and challenge it as unfair.
Cette procédure est simple tant sur le plan technique que juridique, étant donné que la publication des informations est déjà autorisée et que ces informations ne peuvent, par conséquent, ni être jugées inexactes, ni être attaquées par les entreprises.